8 results on '"Donna Roscoe"'
Search Results
2. Data from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
3. Supplementary Figure S1. Study 20120148 - Hematological relapse-free survival for patients in CR1 by MRD level at baseline after at least 3 intensive chemotherapy blocks from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
4. Data from FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
5. Supplementary Table S3. Safety Population - Grade {greater than or equal to} 3 Adverse Reactions from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
6. Supplementary Table S4. Literature Review - Efficacy Outcomes by MRD Log-Group for B-cell ALL CR1 using End-Of-Induction MRD Measurements from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
7. Supplementary Table S5. Literature Review - Efficacy Outcomes by Binary MRD Level for B-cell ALL from FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
8. Supplementary Data from FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.